SSY GROUP (02005) obtained the drug production registration approval for Calcium Gluconate Sodium Chloride Injection (100ml:1g/0.8g) and Metronidazole Sodium Chloride Injection (100ml:0.5g/0.9g).

SSY GROUP (02005) announces that the group has obtained the drug production registration certificate for Calcium Gluconate Sodium Chloride Injection (100ml: 1g / 0.8g) from the China National Medical Products Administration. It belongs to the third category of chemical drugs and is considered equivalent to passing consistency evaluation. Calcium Gluconate Sodium Chloride Injection is mainly used to treat acute hypocalcemia, magnesium poisoning, and fluoride poisoning, and together with the Calcium Gluconate Sodium Chloride Injection (100ml: 2g / 675mg) approved on June 4, 2025, and the Calcium Gluconate Injection (10ml: 1g) approved on July 18, 2025, they form a series of calcium preparation products. The group has obtained the drug production registration certificate for Metronidazole Sodium Chloride Injection (100ml: 0.5g / 0.9g) from the National Medical Products Administration. It belongs to the fourth category of chemical drugs and is considered equivalent to passing consistency evaluation. Metronidazole Sodium Chloride Injection is mainly used for adult gynecologic pelvic inflammatory diseases caused by sensitive bacteria (including endometritis, salpingitis, salpingo-ovarian abscess, pelvic peritonitis, etc.) and for the adjuvant treatment of purulent and gangrenous appendicitis.